Replimune (REPL) Non-Current Deffered Revenue (2018 - 2019)
Replimune (REPL) reported Non-Current Deffered Revenue of $24000.0 for Q1 2019, down 53.85% on a YoY basis from $52000.0 in Q1 2018, and down 85.71% sequentially from $168000.0 in Q4 2018.
Replimune (REPL) Non-Current Deffered Revenue (2018 - 2019) Analysis & Trends
Replimune (REPL) has 2 years of Non-Current Deffered Revenue data on file, last reported at $24000.0 in Q1 2019.
- For the quarter ending Q1 2019, Non-Current Deffered Revenue fell 53.85% year-over-year to $24000.0; the trailing twelve-month figure through Mar 2019 stood at $24000.0 (down 53.85% YoY), and the FY2019 full-year result was $24000.0, down 53.85% from the prior year.
- Non-Current Deffered Revenue eased to $24000.0 in Q1 2019, from $168000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $168000.0 in Q4 2018 to a low of $24000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 24,000.00 |
| Dec 31, 2018 | 168,000.00 |
| Sep 30, 2018 | 36,000.00 |
| Jun 30, 2018 | 43,000.00 |
| Mar 31, 2018 | 52,000.00 |